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ABSTRACT
Introduction Limited cutaneous systemic sclerosis 
(lcSSc) is the most frequent subset of systemic sclerosis. 
Despite this, lcSSc is not the major focus of clinical 
studies. The lack of interventional studies in lcSSc is 
due, in part, to a paucity of relevant outcome measures 
to effectively evaluate this subset. A combined response 
index dedicated to lcSSc would facilitate development 
of well- designed trials and approval of new drugs. The 
objective of this scoping review is to perform a broad and 
comprehensive identification of the outcome measures 
(core set items) within relevant domains, which have been 
used so far to assess lcSSc.
Methods and analysis The planned scoping review 
will be based on the approach proposed by Arksey et 
al and further developed by Levac et al. Development 
and reporting will follow the Preferred Reporting Items 
for Systematic Reviews and Meta- Analyses—Extension 
for Scoping Reviews checklist and guidelines. The 
development of the search strategy was guided by the 
concepts of domains and outcomes based on the Outcome 
Measures in Rheumatology approach and by the different 
names and definitions of SSc, with a specific emphasis on 
their occurrence in clinical trial studies. Two databases will 
be searched: MEDLINE and Embase. Studies in English, 
published from the year 1988 onwards, will be included, 
since 1988 corresponds to the publication of LeRoy’s first 
consensus definition of lcSSc. Data will be extracted and 
analysed using a standardised charting tool.
Ethics and dissemination No ethical approval is 
required for this study. The results will be submitted to 
an international peer- reviewed journal and scientific 
conferences, informing the discussion on which items 
should be included in a combined response index 
dedicated to lcSSc (the CRISTAL project: Combined 
Response Index for Scleroderma Trial Assessing lcSSc).
INTRODUCTION
Rationale
Systemic sclerosis (SSc) or scleroderma is a 
rare autoimmune disorder which includes 
a wide range of clinical manifestations.1 SSc 
is characterised by the association of three 
main features: vasculopathy with Raynaud’s 
phenomenon as the hallmark symptom, 
exuberant fibrosis of the skin and internal 
organs, and immune activation with the 
occurrence of specific autoantibodies and 
inflammatory features such as synovitis and 
tenosynovitis.2
SSc is further subclassified into limited cuta-
neous (lcSSc) and diffuse cutaneous (dcSSc) 
according to 1988 LeRoy and Medsger’s clas-
sification,3 revised in 2001,4 and based on 
the extent of skin involvement by underlying 
fibrosis. LcSSc constitutes 60%–70% of all 
SSc and is considered a milder subphenotype 
of SSc with Raynaud’s phenomenon and GI 
(Gastro- intestinal) involvement as common 
features and pulmonary arterial hyperten-
sion also observed in this subgroup. However, 
accumulating data from European Sclero-
derma Trials and Research group and other 
cohorts show that these and wider visceral 
complications occur in a significant propor-
tion of patients with lcSSc.5 This concept is 
further highlighted by the recent clinical 
trials targeting interstitial lung disease that 
recruited patients with lcSSc as well as dcSSc 
Strengths and limitations of this study
 ► The proposed scoping review will allow for com-
prehensive identification of the outcome measures 
(core set items) and relevant domains, which have 
been incorporated in the assessment of limited cu-
taneous systemic sclerosis (SSc).
 ► The limitations of the scoping review include the 
limited number of databases, the language and 
search terms used.
 ► This scoping review may also under- represent ob-
servational studies that do not explicitly mention the 
words ‘limited SSc’ or ‘limited cutaneous SSc’ in 
their title or abstract.
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(SLS studies (Scleroderma Lung Study I and II)6 7 and 
SENSCIS trial8(Safety and Efficacy of Nintedanib in 
Systemic Sclerosis). Moreover, recent studies focusing on 
quality of life have demonstrated that patients with lcSSc 
experience a significant impairment in their daily quality 
of life and that patients’ experiences of lcSSc have been 
largely overlooked.9 10
Despite this high prevalence of lcSSc and typically earlier 
diagnosis of this specific subtype, there is poor validation 
of dedicated strategies for the management of patients 
with lcSSc. The lack of interventional studies in lcSSc is 
due, in part, to a paucity of relevant outcome measures to 
effectively evaluate this major subset. The range of clin-
ical manifestations of SSc is wide, and clinical items are 
classified within domains, for example, outcomes related 
to vasculopathy such as digital ulcers or outcomes related 
to interstitial lung disease such as the decline of pulmo-
nary function measured through the annual decline of 
forced vital capacity (FVC).11 12 Drug development and 
trials have focused on dcSSc partly due to the availability 
of validated outcome measures, including a relevant 
combined response index, the ACR- CRISS index (Amer-
ican College of Rheumatology- Combined Response 
Index for diffuse Systemic Sclerosis),11 13 14 that captures 
the global improvement of dcSSc. A composite index 
score dedicated to lcSSc that combines different aspects 
of the disease would similarly facilitate development of 
well- designed trials and approval of new drugs to treat 
lcSSc.15 Recent observational studies have highlighted 
the prognostic and predictive values of new imaging tech-
niques and clinical markers such as capillaroscopy or laser 
doppler for vasculopathy, but the relevance of including 
such evaluation tools in combined index approach is 
still to be determined. Identifying and defining relevant 
candidate outcome measures within key SSc- associated 
domains16 to be included in such a combined index is the 
necessary first step for the construction of a future index 
for lcSSc.
Objective
The objective of this scoping review is to perform a broad 
and comprehensive identification of the core set items 
(and/or outcome measures) within relevant domains, 
which have been used so far to assess lcSSc since the 
endorsement of its consensual definition in 1988.
METHODS AND ANALYSIS
We have chosen to conduct a scoping review to perform 
this literature search, based on the methodological frame-
work proposed by Arksey and O’Malley17 and further 
developed by Levac et al.18 Scoping reviews are especially 
effective to identify key factors/characteristics related to 
a concept, in our case, domains related to the assessment 
of lcSSc, and, to examine how research is conducted on a 
certain topic or field, in our case, the outcome measures 
within the identified domains.19 This scoping review will 
comprehensively identify outcome measures in lcSSc 
to inform on how lcSSc has been evaluated to date and 
identify gaps in domains of clinical relevance. This is the 
first step of a project which aims to select the items that 
could be included in a combined response index for 
clinical trials assessing patients with lcSSc (the CRISTAL 
project : Combined Response Index for Scleroderma 
Trial Assessing lcSSc).15
Conceptual framework and key concepts
The concepts of domains and outcomes are based on the 
Outcome Measures in Rheumatology approach.20 This 
approach is made up of two important and sequential 
components: identification of what to measure (domain 
set), for example, in the field of SSc, measuring the impact 
of ‘vasculopathy’, measuring ‘interstitial lung disease’ or 
impact of pain on quality of life and then identification 
of how to measure each of the identified domains using 
relevant instruments or tools (outcome measurement 
set), that is, for the domain ‘vasculopathy’, the number of 
new digital ulcers occurring during follow- up or for the 
domain ‘interstitial lung disease’ change in FVC during 
the considered period or pain visual analogue scale or 
PROMIS (Patient- Reported Outcomes Measurement 
Information System) items to assess the intensity of pain 
and pain interference.21
The systematic identification of outcome measures 
(how to measure a manifestation/visceral involvement) 
and the domains they are related to (which manifesta-
tions of the disease/visceral involvement is measured) 
will inform on how lcSSc has been assessed to date and to 
guide the discussion on which items should be included 
in a combined response index dedicated to lcSSc.
Publication dates and time period
In 1988, LeRoy’s classification of SSc, built on previous 
1980 criteria, crystallised the two main subsets of SSc, lcSSc 
and dcSSc. Prior to LeRoy’s classification, the concept of 
limited SSc was recognised, but several terms were used to 
describe features of this subgroup such as acrosclerosis, 
CREST (Calcinosis- Raynaud's phenomenon- Esophageal 
dysfunction- Sclerodactyly- Telangiectasia), dermatoscle-
rosis or acroscleroderma. These definitions were inconsis-
tent and in contrast with those of generalised scleroderma 
or diffuse scleroderma, with the latter more or less 
matching with the definition of the diffuse cutaneous 
subset.22 The absence of a consensus classification that fully 
captured the concept and components of limited SSc led 
to variable outcome measures and subgrouping criteria. 
The endorsement to define these two subsets (limited vs 
diffuse) of the disease within the 1988 classification criteria 
was based on prognostic data and defined by the extent of 
skin fibrosis involvement. This was a historical milestone in 
the nosology of SSc. Examining articles published before 
1988 could lead to the inclusion of outcomes used to assess 
populations that would not match with the contemporary 
definition of lcSSc and have therefore not been included. 
After 1988, the term CREST/CRST (Calcinosis- Raynaud's 
phenomenon- Sclerodactyly- Telangiectasia) syndrome 
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persisted and overlapped with lcSSc. Based on this, articles 
only mentioning CREST/CRST in their title and abstract 
after 1988 will also be considered for full- text review, and 
full- text assessment will confirm whether the population 
studies match with the contemporary definition of lcSSc.
Scoping review questions
Main question
What are the outcome measures within relevant domains 
that have been used to assess lcSSc since the 1988 LeRoy’s 
classification has been in use?
Secondary questions
How many studies have been published by year?
What types of studies have been published?
General overview of the search strategy
As this scoping review focuses on lcSSc/scleroderma, 
our search terms will focus on studies with orig-
inal data/original articles that explicitly mention 
the subtype ‘limited’ and/or CR(E)ST in their title 
or abstract (#1). Nonetheless, when applying this 
strategy to milestone articles based on the reviewers’ 
expertise,6–8 23–32 we identified a gap, particularly in 
picking up clinical trials. Indeed, many clinical trials 
only mention ‘scleroderma’ in their title or abstract, 
without specifying limited or diffuse, although they 
indeed include patients with lcSSc. This is a major issue 
since the objective is to identify outcome measures to 
be included in a combined response index for clinical 
Table 1 Inclusion and exclusion criteria for the scoping review
Inclusion criteria Exclusion criteria
 ► Language: English
 ► Publication date: after 1988 (or in 1988)
 ► Population:
Population
  For observational studies: titles/abstract mentioning both 
lcSSc and dcSSc will be kept, articles mentioning lcSSc 
only, SSc sine scleroderma, limited SSc, CREST/CRST only 
will be kept as well. When the number of lcSSc patients is 
mentioned, only studies with 20 lcSSc patients or more will 
be included.
  Articles only focusing on localised scleroderma/morphea 
without including systemic sclerosis/systemic scleroderma 
patients will be excluded, articles only focusing on VEDOSS 
only, will be excluded as well. Articles focusing on dcSSc only 
will be excluded. Studies not concerned with human subjects 
or not pertaining to adult will be excluded.
  For clinical/therapeutic trials: Titles/abstract that only 
mention systemic sclerosis/scleroderma without specifying 
dcSSc or lcSSc will be kept, and articles mentioning both 
lcSSc and dcSSc will be kept, articles mentioning lcSSc only, 
SSc sine scleroderma, CREST/CRST or limited SSc will be 
kept as well.
Studies Studies
  For observational studies: observational analytical cross- 
sectional or longitudinal studies, case–control studies, 
prospective and retrospective cohort studies, randomised 
controlled trials, non- randomised controlled trials, Meta- 
analyses and systematic reviews.
  For observational studies: narrative and non- systematic 
reviews, conference abstracts, biography, case report, 
comment, editorial, directory, festschrift, interviews, lectures, 
legal cases, legislation, letter, news, newspaper article, patient 
education handout, popular works, congresses, consensus 
development conference and practice guideline will be 
excluded. Genetic or epigenetic studies will be excluded. 
Observational studies specifically evaluating the prevalence 
of the disease will also be excluded. Translational and basic 
sciences studies, including observational studies dedicated 
to autoantibody testing, will not be considered for full- text 
review as they will not allow to identify new validated outcome 
measures reflecting feeling, functioning or surviving that could 
be used for an acceptable combined response index.
  For clinical/therapeutic trials: randomised controlled trials 
and non- randomised controlled trials will be considered, 
unrandomised or uncontrolled interventional or observational 
studies (before and after studies in routine care) or clinical 
trials evaluating a treatment or a therapeutic strategy will 
also be considered for full- text review. Meta- analysis and 
systematic reviews of clinical/therapeutic trials will also be 
included for full- text review.
  For clinical/therapeutic trials: Narrative reviews focusing on 
clinical trials, conference abstracts, biography, case report, 
comment, editorial, directory, festschrift, interviews, lectures, 
legal cases, legislation, letter, news, newspaper article, patient 
education handout, popular works, congresses, consensus 
development conference and practice guideline will be 
excluded.
  For all: studies without abstract available (only title provided) 
will be excluded.
dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; SSc, systemic sclerosis; VEDOSS, very 
early diagnosis of systemic sclerosis.
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trials. To tackle this issue, we will include in the search 
terms all clinical trials mentioning scleroderma or SSc 
in the title or abstract (#2), even if the word ‘limited’ 
is not mentioned in the title or abstract. For pragmatic 
reasons, observational studies will not be included in 
this #2, only clinical trials, in line with the overall objec-
tive of this scoping review.
Information sources
Electronic databases: PubMed (MEDLINE),  Embase. 
com.
Search terms






exp Scleroderma, Limited/ OR (Scleroderma, Systemic/ 
AND  limited. ti.) OR ((Systemic  scleroderma. mp. OR 
systemic  sclerodermas. mp. OR systemic  sclerosis. mp. OR 
systemic  scleroses. mp. OR  SSc. mp.) ADJ3  limited. mp.) 
OR  lcSSc. mp. OR (( Crest. ti, ab. OR  CRST. ti, ab.) ADJ1 
syndrome*.ti,ab.)
 Embase. com
((‘limited scleroderma’/exp OR (‘systemic sclerosis’/
de AND limited:ti) OR (((‘systemic scleroderma’ OR 
‘systemic sclerodermas’ OR ‘systemic sclerosis’ OR 
‘systemic scleroses’ OR ssc) NEAR/3 limited):ti,ab) OR 
lcssc:ti,ab OR ‘syndrome CREST’/exp OR (((crest OR 
crst) NEAR/1 syndrome*):ti,ab)) NOT ([animals]/lim 
NOT [humans]/lim)) AND (‘article’/it OR ‘article in 
press’/it)
Included
 ► Titles/abstract mentioning both lcSSc and dcSSc 
will be kept, articles mentioning lcSSc only, SSc sine 
scleroderma, limited SSc, CREST/CRST only will 
be kept as well. When the number of lcSSc patients 
is mentioned, only studies with 20 lcSSc patients or 
more will be included.
Excluded
 ► Articles only focusing on localised scleroderma/
morphea without including systemic sclerosis/
systemic scleroderma patients will be excluded, arti-
cles that only mention systemic sclerosis/scleroderma 
without specifying dcSSc or lcSSc will be excluded, 
articles focusing on very early diagnosis of systemic 
sclerosis (VEDOSS)34 only and articles focusing on 
dcSSc only will be excluded as well.
Intervention: n/a.
Comparison: n/a.
Outcomes: n/a as the selection of domains and 
outcome measures is the aim of this scoping review.
Studies
Included articles
 ► Studies written in English.
 ► Original studies including: observational analytical 
cross- sectional or longitudinal studies, case–control 
studies, prospective and retrospective cohort studies, 
randomised controlled trials, non- randomised 
controlled trials, before and after studies, meta- 
analyses and systematic reviews.
Excluded articles
 ► Narrative and non- systematic reviews, conference 
abstracts, biography, case report, comment, editorial, 
directory, festschrift, interviews, lectures, legal cases, 
legislation, letter, news, newspaper article, patient 
education handout, popular works, congresses, 
consensus development conference and practice 
guideline will be excluded. Genetic or epigenetic 
studies will be excluded. Observational studies specif-
ically evaluating the prevalence of the disease will also 
be excluded. Translational and basic sciences studies, 
including observational studies dedicated to autoan-
tibody testing, will not be considered for full- text 
review as they will not allow to identify new validated 
outcome measures reflecting feeling, functioning 
or surviving that could be used for an acceptable 
combined response index.
 ► Studies not concerned with human subjects or not 
pertaining to adult studies will be excluded.
 ► Article published before 1988 and LeRoy’s classifica-
tion (official creation/endorsement of the concept of 





using Sensitivity/precision maximised Cochrane limit*
(Exp Scleroderma, Systemic/OR “Systemic sclero-
derma”.mp. OR “systemic sclerodermas”.mp. OR 
“systemic sclerosis”.mp. OR “systemic scleroses”.mp.) 
AND
*Sensitivity/precision maximised Cochrane filter
(randomized controlled  trial. pt. OR controlled clinical 
trial. pt. OR  randomized. ab. OR  placebo. ab. OR clinical 
trials as  topic. sh. OR  randomly. ab. OR  trial. ti.) not (exp 
animals/ not  humans. sh.)
Included
 ► Titles/abstract that only mention SSc/scleroderma 
without specifying dcSSc or lcSSc will be kept and arti-
cles mentioning both lcSSc and dcSSc will be kept; 
articles mentioning lcSSc only, SSc sine scleroderma, 
CREST/CRST or limited SSc will be kept as well.
Excluded
 ► Articles only focusing on localised scleroderma/
morphea without including systemic sclerosis/
systemic scleroderma patients will be excluded, 
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and articles only focusing on VEDOSS only will be 
excluded as well. Articles focusing on dcSSc only will 
be excluded.
Intervention: randomised controlled trials and unran-
domised controlled trials only.
Comparison: n/a.
Outcomes: n/a as the selection of domains and 
outcome measures is the aim of this scoping review.
Studies
Included articles
 ► Only studies written in English will be considered.
 ► Randomised controlled trials and unrandomised 
controlled trials will be especially considered for this 
#2. Unrandomised or uncontrolled interventional 
or observational studies (before and after studies in 
routine care) or clinical trials evaluating a treatment 
or a therapeutic strategy will also be considered for 
full- text review. Meta- analysis and systematic reviews 
of therapeutic trials will also be included for full- text 
review.
Excluded articles
 ► Reviews, conference abstracts, biography, case report, 
comment, editorial, directory, festschrift, interviews, 
lectures, legal cases, legislation, letter, news, news-
paper article, patient education handout, popular 
works, congresses, consensus development confer-
ence and practice guideline will be excluded, observa-
tional analytical cross- sectional studies, case–control 
studies, prospective and retrospective cohort studies 
will be excluded.
 ► Studies not concerned with human subjects or not 
pertaining to adults will be excluded.
 ► Article published before 1988 and LeRoy’s classifica-
tion (official creation/endorsement of the concept of 
limited SSc) will be excluded.
Synthesis of eligibility criteria
Inclusion criteria
1. Language: English.
2. Publication date: after 1988 and Leroy’s classification.
3. Population.
For observational studies
Titles/abstract mentioning both lcSSc and dcSSc will be 
kept, articles mentioning lcSSc only, SSc sine scleroderma, 
limited SSc and CREST/CRST only will be kept as well. 
When the number of lcSSc patients is mentioned, only 
studies with 20 lcSSc patients or more will be included.
For clinical/therapeutic trials
Titles/abstract that only mention SSc/scleroderma 
without specifying dcSSc or lcSSc will be kept, and articles 
mentioning both lcSSc and dcSSc will be kept, articles 
mentioning lcSSc only, SSc sine scleroderma, CREST/
CRST or limited SSc will be kept as well.
4. Studies
For observational studies observational analytical cross- 
sectional or longitudinal studies, case–control studies, 
prospective and retrospective cohort studies, randomised 
controlled trials, non- randomised controlled trials, meta- 
analyses and systematic reviews.
For clinical/therapeutic trials
Randomised controlled trials and non- randomised 
controlled trials will be considered, unrandomised or 
uncontrolled interventional or observational studies 
(before and after studies in routine care) or clinical 
trials evaluating a treatment or a therapeutic strategy will 
also be considered for full- text review. Meta- analysis and 
systematic reviews of clinical/therapeutic trials will also 
be included for full- text review.
Exclusion criteria
1. Population
Articles only focusing on localised scleroderma/
morphea without including SSc/systemic scleroderma 
patients will be excluded, articles only focusing on 
VEDOSS only, will be excluded as well. Articles focusing 
on dcSSc only will be excluded. Studies not concerned 




Narrative and non- systematic reviews, conference 
abstracts, biography, case report, comment, editorial, 
directory, festschrift, interviews, lectures, legal cases, legis-
lation, letter, news, newspaper article, patient education 
handout, popular works, congresses, consensus develop-
ment conference and practice guideline will be excluded. 
Genetic or epigenetic studies will be excluded. Obser-
vational studies specifically evaluating the prevalence of 
the disease will also be excluded. Translational and basic 
sciences studies, including observational studies dedi-
cated to autoantibody testing, will not be considered 
for full- text review as they will not allow to identify new 
validated outcome measures reflecting feeling, func-
tioning or surviving, that could be used for an acceptable 
combined response index.
For clinical/therapeutic trials
Narrative reviews focusing on clinical trials, conference 
abstracts, biography, case report, comment, editorial, 
directory, festschrift, interviews, lectures, legal cases, legis-
lation, letter, news, newspaper article, patient education 
handout, popular works, congresses, consensus develop-
ment conference and practice guideline will be excluded.
For all
Studies without abstract available (only title provided) 
will be excluded (table 1).
Reporting of protocol and study records
This study protocol follows PRISMA- ScR guidelines35 
and PRISMA guidelines for the publication of systematic 
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review protocols,36 with specific adaptations for this 
scoping review protocol.
Data management will be housed through Covidence 
(https://www. covidence. org/ home), under the supervi-
sion of DK and MHB.
DR, JP, MH, RS, AL and FZ will screen citations and 
review for eligibility and inclusion based on the eligibility 
criteria and the article selection template (tables 1 and 2). 
AL will assess all the titles (T) and abstracts (A), and the 
other five reviewers will evaluate 1/5th of T/A to ensure 
that all articles will be double checked. Inter- rater agree-
ment will be evaluated using Cohen’s Kappa statistics. A 
first test of agreement will be performed based on 50 cita-
tions. If Kappa coefficients are under 0.8, we will evaluate 
the disagreements and understand the reason to correct 
misunderstanding and ensure consistency for the rest of 
the review process. T and A will then be reviewed for the 
entire article list. Any disagreements between reviewers 
will be reviewed and resolved by DK and/or MHB. If 
uncertainty persists, the manuscript will be included for 
comprehensiveness. Where there is lack of data clarity 
pertaining to exclusion criteria in manuscripts, mentors 
will be contacted to discuss this issue. Agreement between 
pairs for overlapping citations will also be assessed using 
Cohen’s Kappa statistics at the end of the process. After 
article selection, the data extraction template (table 3) 
for full- text review will be evaluated by two reviewers on 
a sample of 20% of included studies to adjust its sensi-
tivity. Once the template is finalised, one reviewer will 
then perform the analysis, and the second reviewer will 
independently check a sample of the total of 20% arti-
cles, for accuracy. Any disagreements will be reviewed and 
resolved by DK and/or MHB. Citation searching will be 
applied to identify additional studies through checking 
Table 2 General template for title and abstract screening
Questions
1. Is the article written in English? □ Yes □ Νο
2. Is the article after 1988 (or published in 1988)? □ Yes □ Νο
3. Is this an observational study based on primary 
data or is this a systematic review/metanalysis 
published as original article, And is not a genetic 
or epigenetic or prevalence or basic science/
biomarker study?
□ Yes □ Νο
 ► If yes, if the number of patients from the above 
mentioned subgroup is specified, is it 20 or 
more?
 ► If 1–2–3 fulfilled, does title or abstract mention 
lcSSc or sine or lSSc or CREST/CRST?
□ Yes □ Νο
□ Yes □ Νο
□ Uncertain: 
needs full- text 
reviewing
If 1–2 fulfilled and if the title or abstract does not 
mention lcSSc or sine or lSSc or CREST/CRST,
 ► Which does not exclusively concern dcSSc 
patients ?
 ► is this a randomizedrandomised controlled 
trial, non- randomizedrandomised controlled 
trial, an unrandomiszed or uncontrolled 
interventional or observational studies (before 
and after studies in routine care) or clinical 
trial evaluating a treatment or a therapeutic 
strategy ?
□ Yes □ Νο
□ Uncertain: 
needs full text 
reviewing
dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited 
cutaneous systemic sclerosis; lSSc, limited systemic sclerosis.
Table 3 Preliminary charting table for data extraction
Item Description
Journal   
First author   
Year publication   
Patient population □ dcSSc and lcSSc (including 
lSSc, sine and CREST)
□ lcSSc only (including lSSc, sine 
and CREST)
Number of patients evaluated 
(total)
  
Number of patients with lcSSc 
(including lSSc, sine and 
CREST)
  
Study type □ Observational cross- sectional 
study (pro or retrospective)
□ Observational longitudinal study 
(pro or retrospective)
□ Case–control study
□ Randomised clinical trial
□ Unrandomised clinical trial
□ Basic sciences (biomarkers)
Domain 1 as explicitly 
mentioned in the article
  
Outcome 1 (of D1) with 
assessment methods
  
Outcome 2 (of D1) with 
assessment methods
  
Add as many outcomes as 
necessary
  
(…)   
Domain 2 as explicitly 
mentioned in the article
  
Outcome 1 (of D2) with 
assessment methods
  
Outcome 2 (of D2) with 
assessment methods
  
Add as many outcomes as 
necessary
  
(…)   
No domain explicitly 
mentioned in the article (Dn/a)
  
Outcome 1 (of Dn/a) with 
assessment methods
  
Outcome 2 (of Dn/a) with 
assessment methods
  
Add as many outcomes as 
necessary
  
(…)   
dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited 
cutaneous systemic sclerosis; lSSc, limited systemic sclerosis.
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of reference lists of primary studies. Although quality 
appraisal is typically necessary for systematic literature 
reviews and meta- analyses, using evaluation tools such 
as the Jadad scale,37 the Cochrane risk of bias tool38 or 
the Newcastle- Ottawa Scale for non- randomised studies39 
our focus is to conduct a scoping review to determine 
domains and outcome measures that have been studied 
in lcSSc. As such, quality appraisal is not planned. We 
intend to start title and abstract selection on Covidence 
starting January 2021.
Presentation of the results
We expect to present the main results of this scoping 
review, with a least one table summarising domains and 
identified outcomes. For the main domains of interest, 
their frequency in the literature will also be provided in a 
table. Identified gaps and main issues concerning the lack 
of outcome measures and/or their poor use will also be 
highlighted in a third table. In the end, a comprehensive 
map of the main domains and outcomes will be provided 
within a dedicated graphical abstract or figure.
ETHICS AND DISSEMINATION
This scoping review is based on the analysis of published 
scientific literature without involving any patient, any new 
clinical or fundamental research or any type of personal 
information. Therefore, no ethical approval is required. 
The results of this scoping review will be submitted for 
publication in a peer- reviewed journal and will provide 
an overview of domains and items that are captured in 
observational cohorts and clinical trials in lcSSc and can 
be used for a combined index. The results concerning 
these domains and items, and each step of the creation of 
this combined index will also be submitted for presenta-
tion in international congresses of rheumatology.
Patient and public involvement
This scoping review plans to analyse the published scien-
tific literature; no patients are involved for this specific 
analysis. The overall objective of the CRISTAL project 
is to develop a combined response index for lcSSc with 
input from the patient partners, clinicians with expertise 
in SSc and methodologists. All the steps of the project 
and patient partners involvement have been published 
previously.15
STRENGTHS, LIMITATIONS AND DISCUSSION POINTS
 ► The proposed scoping review will allow a broad 
and comprehensive identification of the outcome 
measures (core set items) within relevant domains, 
which have been used so far to assess lcSSc. The 
specific emphasis on clinical trials including patients 
with lcSSc will ensure the identification of relevant 
outcome measures used so far and their mapping 
within key domains, eventually highlighting gaps and 
main issues concerning the lack of outcome measures 
and/or their poor use.
 ► Although comprehensive, this study design has 
limitations regarding the number of databases, the 
language and search terms used and may under- 
represent observational studies that do not explicitly 
mention the word ‘limited SSc’ or ‘limited cutaneous 
SSc’ in their title or abstract.
 ► By focusing on articles published after 1988, this 
scoping review may not capture the outcome meas-
ures used to assess equivalent subsets of lcSSc before 
this date, but this will ensure that the population 
included match with the contemporary definition of 
lcSSc.
 ► For this first phase of the initiative, we are seeking to 
identify relevant domains and outcomes as opposed 
to evaluate their specific properties in lcSSc. Never-
theless, the several clinical trials to be evaluated 
will not report results solely in lcSSc patients, which 
constitutes a limitation of our protocol.
 ► Regulatory agencies emphasise outcomes should 
reflect how patients feel, function and/or survive. 
With this in mind, as the main objective is to iden-
tify domains and outcomes that could be incorpo-
rated in a combined response index, we have not 
included congress databases or studies on explora-
tory biomarkers or epigenetic/genetic studies. Such 
a selection will limit the comprehensiveness of this 
scoping review but will insure its coherence with the 
global objective of the project. Regarding this main 
objective, to remain consistent with the comprehen-
sive concept of scoping review, and considering that 
we are not performing a systematic review or meta- 
analysis, we will not evaluate quality appraisal, and this 
could be considered as a limitation of this protocol.
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